Design Therapeutics DSGN
NASDAQ DSGN
$10.60 -0.20 (-1.85%)
As of: Nov 10, 2026 · 12:59 PM EST

Design Therapeutics (DSGN) EBIT Margin (2020)

Updated

Design Therapeutics (DSGN) reported EBIT Margin of -11700.00% for Q4 2020, up 215.00 percentage points from the prior quarter.

Analysis

Design Therapeutics (DSGN) EBIT Margin (2020) Analysis & Trends

For FY2020, Design Therapeutics posted EBIT Margin of -3685.84%.

  • Five-year quarterly EBIT Margin spans a low of -11915.00% in Q3 2020 and a high of -438.73% in Q1 2020.
  • Per Business Quant data, the three quarters before Q4 2020 came in at -11915.00% (Q3 2020), -4719.35% (Q2 2020) and -438.73% (Q1 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 52.42%
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 24.35%
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 36.01%
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 30.89%
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 32.97%
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 20.57%
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 35.79%
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 41.71%
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 32.98%
10 Design Therapeutics 678.89 Mn -179.78 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 -11,700.00%
Sep 30, 2020 -11,915.00%
Jun 30, 2020 -4,719.35%
Mar 31, 2020 -438.73%
API Access

Design Therapeutics EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=DSGN&period=max&api_key=YOUR_API_KEY